IBDEI10K ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,16487,2)
;;=^5001941
;;^UTILITY(U,$J,358.3,16488,0)
;;=D06.0^^61^775^47
;;^UTILITY(U,$J,358.3,16488,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16488,1,3,0)
;;=3^Carcinoma in Situ of Endocervix
;;^UTILITY(U,$J,358.3,16488,1,4,0)
;;=4^D06.0
;;^UTILITY(U,$J,358.3,16488,2)
;;=^5001938
;;^UTILITY(U,$J,358.3,16489,0)
;;=D06.1^^61^775^48
;;^UTILITY(U,$J,358.3,16489,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16489,1,3,0)
;;=3^Carcinoma in Situ of Exocervix
;;^UTILITY(U,$J,358.3,16489,1,4,0)
;;=4^D06.1
;;^UTILITY(U,$J,358.3,16489,2)
;;=^5001939
;;^UTILITY(U,$J,358.3,16490,0)
;;=D06.7^^61^775^46
;;^UTILITY(U,$J,358.3,16490,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16490,1,3,0)
;;=3^Carcinoma in Situ of Cervix,Other Parts
;;^UTILITY(U,$J,358.3,16490,1,4,0)
;;=4^D06.7
;;^UTILITY(U,$J,358.3,16490,2)
;;=^5001940
;;^UTILITY(U,$J,358.3,16491,0)
;;=D04.9^^61^775^49
;;^UTILITY(U,$J,358.3,16491,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16491,1,3,0)
;;=3^Carcinoma in Situ of Skin
;;^UTILITY(U,$J,358.3,16491,1,4,0)
;;=4^D04.9
;;^UTILITY(U,$J,358.3,16491,2)
;;=^5001925
;;^UTILITY(U,$J,358.3,16492,0)
;;=C91.11^^61^775^52
;;^UTILITY(U,$J,358.3,16492,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16492,1,3,0)
;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
;;^UTILITY(U,$J,358.3,16492,1,4,0)
;;=4^C91.11
;;^UTILITY(U,$J,358.3,16492,2)
;;=^5001766
;;^UTILITY(U,$J,358.3,16493,0)
;;=C91.10^^61^775^53
;;^UTILITY(U,$J,358.3,16493,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16493,1,3,0)
;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
;;^UTILITY(U,$J,358.3,16493,1,4,0)
;;=4^C91.10
;;^UTILITY(U,$J,358.3,16493,2)
;;=^5001765
;;^UTILITY(U,$J,358.3,16494,0)
;;=C92.11^^61^775^54
;;^UTILITY(U,$J,358.3,16494,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16494,1,3,0)
;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
;;^UTILITY(U,$J,358.3,16494,1,4,0)
;;=4^C92.11
;;^UTILITY(U,$J,358.3,16494,2)
;;=^5001793
;;^UTILITY(U,$J,358.3,16495,0)
;;=C92.10^^61^775^55
;;^UTILITY(U,$J,358.3,16495,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16495,1,3,0)
;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
;;^UTILITY(U,$J,358.3,16495,1,4,0)
;;=4^C92.10
;;^UTILITY(U,$J,358.3,16495,2)
;;=^5001792
;;^UTILITY(U,$J,358.3,16496,0)
;;=D47.1^^61^775^56
;;^UTILITY(U,$J,358.3,16496,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16496,1,3,0)
;;=3^Chronic Myeloproliferative Disease
;;^UTILITY(U,$J,358.3,16496,1,4,0)
;;=4^D47.1
;;^UTILITY(U,$J,358.3,16496,2)
;;=^5002256
;;^UTILITY(U,$J,358.3,16497,0)
;;=C82.69^^61^775^57
;;^UTILITY(U,$J,358.3,16497,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16497,1,3,0)
;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,16497,1,4,0)
;;=4^C82.69
;;^UTILITY(U,$J,358.3,16497,2)
;;=^5001530
;;^UTILITY(U,$J,358.3,16498,0)
;;=C82.60^^61^775^58
;;^UTILITY(U,$J,358.3,16498,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16498,1,3,0)
;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
;;^UTILITY(U,$J,358.3,16498,1,4,0)
;;=4^C82.60
;;^UTILITY(U,$J,358.3,16498,2)
;;=^5001521
;;^UTILITY(U,$J,358.3,16499,0)
;;=D56.2^^61^775^59
;;^UTILITY(U,$J,358.3,16499,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,16499,1,3,0)
;;=3^Delta-Beta Thalassemia
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI10K 3748 printed Nov 22, 2024@17:09:35 Page 2
IBDEI10K ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,16487,2)
+2 ;;=^5001941
+3 ;;^UTILITY(U,$J,358.3,16488,0)
+4 ;;=D06.0^^61^775^47
+5 ;;^UTILITY(U,$J,358.3,16488,1,0)
+6 ;;=^358.31IA^4^2
+7 ;;^UTILITY(U,$J,358.3,16488,1,3,0)
+8 ;;=3^Carcinoma in Situ of Endocervix
+9 ;;^UTILITY(U,$J,358.3,16488,1,4,0)
+10 ;;=4^D06.0
+11 ;;^UTILITY(U,$J,358.3,16488,2)
+12 ;;=^5001938
+13 ;;^UTILITY(U,$J,358.3,16489,0)
+14 ;;=D06.1^^61^775^48
+15 ;;^UTILITY(U,$J,358.3,16489,1,0)
+16 ;;=^358.31IA^4^2
+17 ;;^UTILITY(U,$J,358.3,16489,1,3,0)
+18 ;;=3^Carcinoma in Situ of Exocervix
+19 ;;^UTILITY(U,$J,358.3,16489,1,4,0)
+20 ;;=4^D06.1
+21 ;;^UTILITY(U,$J,358.3,16489,2)
+22 ;;=^5001939
+23 ;;^UTILITY(U,$J,358.3,16490,0)
+24 ;;=D06.7^^61^775^46
+25 ;;^UTILITY(U,$J,358.3,16490,1,0)
+26 ;;=^358.31IA^4^2
+27 ;;^UTILITY(U,$J,358.3,16490,1,3,0)
+28 ;;=3^Carcinoma in Situ of Cervix,Other Parts
+29 ;;^UTILITY(U,$J,358.3,16490,1,4,0)
+30 ;;=4^D06.7
+31 ;;^UTILITY(U,$J,358.3,16490,2)
+32 ;;=^5001940
+33 ;;^UTILITY(U,$J,358.3,16491,0)
+34 ;;=D04.9^^61^775^49
+35 ;;^UTILITY(U,$J,358.3,16491,1,0)
+36 ;;=^358.31IA^4^2
+37 ;;^UTILITY(U,$J,358.3,16491,1,3,0)
+38 ;;=3^Carcinoma in Situ of Skin
+39 ;;^UTILITY(U,$J,358.3,16491,1,4,0)
+40 ;;=4^D04.9
+41 ;;^UTILITY(U,$J,358.3,16491,2)
+42 ;;=^5001925
+43 ;;^UTILITY(U,$J,358.3,16492,0)
+44 ;;=C91.11^^61^775^52
+45 ;;^UTILITY(U,$J,358.3,16492,1,0)
+46 ;;=^358.31IA^4^2
+47 ;;^UTILITY(U,$J,358.3,16492,1,3,0)
+48 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
+49 ;;^UTILITY(U,$J,358.3,16492,1,4,0)
+50 ;;=4^C91.11
+51 ;;^UTILITY(U,$J,358.3,16492,2)
+52 ;;=^5001766
+53 ;;^UTILITY(U,$J,358.3,16493,0)
+54 ;;=C91.10^^61^775^53
+55 ;;^UTILITY(U,$J,358.3,16493,1,0)
+56 ;;=^358.31IA^4^2
+57 ;;^UTILITY(U,$J,358.3,16493,1,3,0)
+58 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
+59 ;;^UTILITY(U,$J,358.3,16493,1,4,0)
+60 ;;=4^C91.10
+61 ;;^UTILITY(U,$J,358.3,16493,2)
+62 ;;=^5001765
+63 ;;^UTILITY(U,$J,358.3,16494,0)
+64 ;;=C92.11^^61^775^54
+65 ;;^UTILITY(U,$J,358.3,16494,1,0)
+66 ;;=^358.31IA^4^2
+67 ;;^UTILITY(U,$J,358.3,16494,1,3,0)
+68 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
+69 ;;^UTILITY(U,$J,358.3,16494,1,4,0)
+70 ;;=4^C92.11
+71 ;;^UTILITY(U,$J,358.3,16494,2)
+72 ;;=^5001793
+73 ;;^UTILITY(U,$J,358.3,16495,0)
+74 ;;=C92.10^^61^775^55
+75 ;;^UTILITY(U,$J,358.3,16495,1,0)
+76 ;;=^358.31IA^4^2
+77 ;;^UTILITY(U,$J,358.3,16495,1,3,0)
+78 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
+79 ;;^UTILITY(U,$J,358.3,16495,1,4,0)
+80 ;;=4^C92.10
+81 ;;^UTILITY(U,$J,358.3,16495,2)
+82 ;;=^5001792
+83 ;;^UTILITY(U,$J,358.3,16496,0)
+84 ;;=D47.1^^61^775^56
+85 ;;^UTILITY(U,$J,358.3,16496,1,0)
+86 ;;=^358.31IA^4^2
+87 ;;^UTILITY(U,$J,358.3,16496,1,3,0)
+88 ;;=3^Chronic Myeloproliferative Disease
+89 ;;^UTILITY(U,$J,358.3,16496,1,4,0)
+90 ;;=4^D47.1
+91 ;;^UTILITY(U,$J,358.3,16496,2)
+92 ;;=^5002256
+93 ;;^UTILITY(U,$J,358.3,16497,0)
+94 ;;=C82.69^^61^775^57
+95 ;;^UTILITY(U,$J,358.3,16497,1,0)
+96 ;;=^358.31IA^4^2
+97 ;;^UTILITY(U,$J,358.3,16497,1,3,0)
+98 ;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
+99 ;;^UTILITY(U,$J,358.3,16497,1,4,0)
+100 ;;=4^C82.69
+101 ;;^UTILITY(U,$J,358.3,16497,2)
+102 ;;=^5001530
+103 ;;^UTILITY(U,$J,358.3,16498,0)
+104 ;;=C82.60^^61^775^58
+105 ;;^UTILITY(U,$J,358.3,16498,1,0)
+106 ;;=^358.31IA^4^2
+107 ;;^UTILITY(U,$J,358.3,16498,1,3,0)
+108 ;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
+109 ;;^UTILITY(U,$J,358.3,16498,1,4,0)
+110 ;;=4^C82.60
+111 ;;^UTILITY(U,$J,358.3,16498,2)
+112 ;;=^5001521
+113 ;;^UTILITY(U,$J,358.3,16499,0)
+114 ;;=D56.2^^61^775^59
+115 ;;^UTILITY(U,$J,358.3,16499,1,0)
+116 ;;=^358.31IA^4^2
+117 ;;^UTILITY(U,$J,358.3,16499,1,3,0)
+118 ;;=3^Delta-Beta Thalassemia
